טוען...
EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors
PURPOSE: Mutant selective irreversible pyrimidine based EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. However, little is known about how cancers develop...
שמור ב:
| הוצא לאור ב: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4791951/ https://ncbi.nlm.nih.gov/pubmed/25948633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2789 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|